These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6182005)

  • 21. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 22. An unexpected effect of L-5 hydroxytryptophan-ethyl-ester combined with a peripheral decarboxylase inhibitor on human serum prolactin.
    van Praag HM; Korf J; Lequin RM
    Psychopharmacol Commun; 1976; 2(5-6):369-78. PubMed ID: 1088302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of benserazide and carbidopa on the metabolism of L-tryptophan by isolated rat liver cells.
    Smith SA; Pogson CI
    Biochem Pharmacol; 1981 Mar; 30(6):623-8. PubMed ID: 7271899
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of a decarboxylase inhibitor (Ro 4-4602) on 5-HTP induced muricide blockade in rats.
    Bocknik SE; Kulkarni AS
    Neuropharmacology; 1974 Apr; 13(4):279-81. PubMed ID: 4546783
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of benserazide, carbidopa and isoniazid administration on tryptophan-nicotinamide nucleotide metabolism in the rat.
    Bender DA
    Biochem Pharmacol; 1980 Aug; 29(15):2099-104. PubMed ID: 6447505
    [No Abstract]   [Full Text] [Related]  

  • 26. Systemic and in vitro effects of GAD and GABA-T inhibitors on AADC activity and of AADC inhibitors on GAD.
    Giorgi O; Rubio MC
    Gen Pharmacol; 1981; 12(4):217-23. PubMed ID: 7250670
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition in vitro of the enzymes of the oxidative pathway of tryptophan metabolism and of nicotinamide nucleotide synthesis by benserazide, carbidopa and isoniazid.
    Bender DA
    Biochem Pharmacol; 1980 Mar; 29(5):707-12. PubMed ID: 20227944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD
    Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-DOPA: centrally mediated emission of seminal fluid in male rats.
    Friedman E; Gershon S
    Life Sci I; 1972 May; 11(9):435-40. PubMed ID: 4656863
    [No Abstract]   [Full Text] [Related]  

  • 30. Probenecid-induced increase of 5-hydroxytryptamine synthesis in rat brain, as measured by formation of 5-hydroxytryptophan.
    van Wijk M; Sebens JB; Korf J
    Psychopharmacology (Berl); 1979 Feb; 60(3):229-35. PubMed ID: 108699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased gastric cholinergic activity evoked by 5-hydroxy-L-tryptophan in the rat.
    Sanger GJ; McClelland CM
    Eur J Pharmacol; 1986 Aug; 127(3):179-85. PubMed ID: 3019729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of L-5HTP with and without carbidopa on plasma beta-endorphin and pain perception: possible implications in migraine prophylaxis.
    Genazzani AR; Sandrini G; Facchinetti F; Rizzo V; Alfonsi E; Sances G; Calvani M; Nappi G
    Cephalalgia; 1986 Sep; 6(3):175-9. PubMed ID: 2945645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of benserazide on the levels of pineal 5-hydroxytryptamine, melatonin synthesising enzymes and serum melatonin.
    Ho AK; Smith JA
    Biochem Pharmacol; 1982 Jul; 31(13):2251-5. PubMed ID: 6889864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a decarboxylase inhibitor on the Dopa and 5-HTP induced changes in the locomotor-like discharge pattern of rabbit hind limb nerves.
    Viala D; Buser P
    Psychopharmacologia; 1974; 40(3):225-33. PubMed ID: 4548539
    [No Abstract]   [Full Text] [Related]  

  • 35. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state.
    Magnussen I; Nielsen-Kudsk F
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):257-62. PubMed ID: 6966118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of carbidopa on the cerebral accumulation of exogenous L-5-hydroxytryptophan in mice.
    Magnussen I
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):199-202. PubMed ID: 6334429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The action L-dopa on sexual behaviour of male rats.
    Da Prada M; Carruba M; Saner A; O'Brien A; Pletscher A
    Brain Res; 1973 Jun; 55(2):383-9. PubMed ID: 4541349
    [No Abstract]   [Full Text] [Related]  

  • 39. L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain.
    Löscher W; Pagliusi SR; Müller F
    Neuropharmacology; 1984 Sep; 23(9):1041-8. PubMed ID: 6083501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzymic studies on the metabolism of 5-hydroxyindoles in the brain.
    Kido R; Noguchi T; Minatogawa Y
    Acta Vitaminol Enzymol; 1975; 29(1-6):344-5. PubMed ID: 1088593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.